Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q1 EPS of ($0.03), $0.09 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $7.29 million versus the consensus estimate of $7.55 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.